



HNL/CS/1731  
August 12, 2021

**The General Manager,**  
Pakistan Stock Exchange Limited,  
Stock Exchange Building,  
Stock Exchange Road,  
**KARACHI.**

**Subject: FINANCIAL RESULTS FOR THE HALF YEAR  
ENDED JUNE 30, 2021**

Dear Sir,

It is to inform you that the Board of Directors of our Company in the meeting held on Thursday August 12, 2021, at 11:00 a.m., at Corporate Office, (Office No. 901, 9<sup>th</sup> Floor, Tricon Corporate Center, 73 E, Jail Road, Lahore) approved the financial statements for the half year ended June 30, 2021.

**Financial Results of the Company and Consolidated Financial Results with its subsidiary are attached herewith as Annexure I and Annexure II, respectively.**

The Half Yearly Report of the Company for the period ended June 30, 2021, will be transmitted through PUCARS separately, within the specified time.

Thanking you and assurances of our highest considerations.

Yours faithfully,

**KHADIM HUSSAIN MIRZA,**  
Company Secretary

Encl: a.a.

- **The Securities & Exchange Commission of Pakistan, Islamabad**
- **The Securities & Exchange Commission of Pakistan,  
Companies Registration Office, Lahore.**
- **Central Depository Company of Pakistan Limited, Karachi**

**Highnoon Laboratories Limited: Registered Office & Plant:** 17.5 KM, Multan Road, Lahore - 53700, Pakistan.

**Corporate Office:** Office No. 901, 9th Floor, Tricon Corporate Center, 73 E, Jail Road, Lahore - 54660, Pakistan.

**UAN:** +92 (0) 304 1110 465 | **Phone:** +92 (42) 36407346 | **Fax:** 92 (42) 37510037 | **Email:** info@highnoon.com.pk | **URL:** www.highnoon-labs.com



Annexure - I

HIGHNOON LABORATORIES LIMITED  
UNCONSOLIDATED CONDENSED INTERIM STATEMENT OF PROFIT OR LOSS (UN-AUDITED)  
FOR THE SIX MONTHS ENDED 30 JUNE 2021

Note	Six Month Period Ended		Three Month Period Ended		
	30 June	30 June	30 June	30 June	
	2021	2020	2021	2020	
	Rupees	Rupees	Rupees	Rupees	
Revenue from contract with customers- net	16	6,369,964,698	5,056,869,657	3,252,878,543	2,491,263,754
Cost of revenue	17	(3,215,838,665)	(2,601,328,811)	(1,623,080,798)	(1,227,479,986)
<b>Gross profit</b>		<b>3,154,126,033</b>	<b>2,455,540,846</b>	<b>1,629,797,745</b>	<b>1,263,783,768</b>
Distribution, selling and promotional expenses		(1,694,908,924)	(1,306,173,351)	(884,597,449)	(650,409,129)
Administrative and general expenses		(246,815,371)	(204,316,926)	(123,246,409)	(100,060,133)
Research and development expenses		(4,604,407)	(2,749,978)	(2,570,681)	(1,413,948)
Other operating expenses		(110,363,866)	(77,582,427)	(59,875,570)	(41,636,267)
		(2,056,692,568)	(1,590,822,682)	(1,070,290,109)	(793,519,477)
<b>Operating profit</b>		<b>1,097,433,465</b>	<b>864,718,164</b>	<b>559,507,636</b>	<b>470,264,291</b>
Other income	18	73,008,157	40,595,931	42,445,525	25,313,266
Finance costs		(14,803,247)	(8,436,652)	(7,378,873)	(3,823,863)
<b>Profit before taxation</b>		<b>1,155,638,375</b>	<b>896,877,443</b>	<b>594,574,288</b>	<b>491,753,694</b>
Taxation		(305,607,585)	(245,231,170)	(153,567,083)	(127,669,238)
<b>Profit for the period</b>		<b>850,030,790</b>	<b>651,646,273</b>	<b>441,007,205</b>	<b>364,084,456</b>
Earnings per share - basic and diluted		22.32	17.11	11.58	9.56





Annexure - II

HIGHNOON LABORATORIES LIMITED  
 CONSOLIDATED CONDENSED INTERIM STATEMENT OF PROFIT OR LOSS (Un-audited)  
 FOR SIX MONTHS ENDED 30 JUNE 2021

	Note	Six Month Period Ended		Three Month Period Ended	
		30 June	30 June	30 June	30 June
		2021	2020	2021	2020
		Rupees	Rupees	Rupees	Rupees
Revenue from Contract with customers- net	15	6,369,964,698	5,056,869,657	3,252,878,543	2,491,263,754
Cost of revenue	16	3,155,732,362	2,562,780,117	1,598,207,306	1,216,324,432
<b>Gross profit</b>		<b>3,214,232,336</b>	<b>2,494,089,540</b>	<b>1,654,671,237</b>	<b>1,274,939,322</b>
Distribution, selling and promotional expenses		1,694,908,924	1,306,173,351	884,597,449	650,767,998
Administrative and general expenses		266,335,130	217,626,697	132,296,729	108,982,365
Research and development expenses		4,604,407	2,749,978	2,570,681	1,413,948
Other operating expenses		112,310,576	78,181,604	60,984,997	41,483,321
		<b>2,078,159,037</b>	<b>1,604,731,630</b>	<b>1,080,449,856</b>	<b>802,647,632</b>
<b>Operating Profit</b>		<b>1,136,073,299</b>	<b>889,357,910</b>	<b>574,221,381</b>	<b>472,291,690</b>
Other income		72,585,602	39,858,852	42,390,460	36,580,430
Finance costs	17	(18,486,455)	(12,788,920)	(9,107,267)	(10,146,919)
<b>Profit before taxation</b>		<b>1,190,172,446</b>	<b>916,427,842</b>	<b>607,504,574</b>	<b>498,725,201</b>
Taxation		(312,101,684)	(247,286,750)	(156,818,760)	(122,996,186)
<b>Profit for the period</b>		<b>878,070,762</b>	<b>669,141,092</b>	<b>450,685,814</b>	<b>375,729,015</b>
Shareholders of the Parent		878,070,762	669,141,092	450,685,814	375,729,015
Non Controlling Interest		-	-	-	-
		<b>878,070,762</b>	<b>669,141,092</b>	<b>450,685,814</b>	<b>375,729,015</b>

	Restated	Restated
Earnings per share - basic and diluted	23.06	17.57
	11.84	9.87

